Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Price, Quote, News and Overview

NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD

1.07  -0.02 (-1.83%)

CNSP Quote, Performance and Key Statistics

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (4/28/2025, 11:31:07 AM)

1.07

-0.02 (-1.83%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High800
52 Week Low0.77
Market Cap3.15M
Shares2.94M
Float2.93M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO11-08 2019-11-08


CNSP short term performance overview.The bars show the price performance of CNSP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60 -80

CNSP long term performance overview.The bars show the price performance of CNSP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CNSP is 1.07 USD. In the past month the price decreased by -17.42%. In the past year, price decreased by -99.8%.

CNS PHARMACEUTICALS INC / CNSP Daily stock chart

CNSP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 66.9 824.50B
JNJ JOHNSON & JOHNSON 15.44 373.91B
NVO NOVO-NORDISK A/S-SPONS ADR 18.2 278.77B
NVS NOVARTIS AG-SPONSORED ADR 14.23 223.15B
AZN ASTRAZENECA PLC-SPONS ADR 17 218.70B
MRK MERCK & CO. INC. 10.7 209.82B
PFE PFIZER INC 7.42 130.84B
SNY SANOFI-ADR 13.75 129.58B
BMY BRISTOL-MYERS SQUIBB CO 6.6 98.58B
GSK GSK PLC-SPON ADR 8.74 77.05B
ZTS ZOETIS INC 25.99 68.63B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.96 47.71B

About CNSP

Company Profile

CNSP logo image CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Company Info

CNS PHARMACEUTICALS INC

2100 West Loop S Ste 900

Houston TEXAS 77027 US

CEO: John Climaco

Employees: 4

Company Website: https://cnspharma.com/

Investor Relations: https://ir.cnspharma.com/

Phone: 18009469185

CNS PHARMACEUTICALS INC / CNSP FAQ

What is the stock price of CNS PHARMACEUTICALS INC today?

The current stock price of CNSP is 1.07 USD. The price decreased by -1.83% in the last trading session.


What is the ticker symbol for CNS PHARMACEUTICALS INC stock?

The exchange symbol of CNS PHARMACEUTICALS INC is CNSP and it is listed on the Nasdaq exchange.


On which exchange is CNSP stock listed?

CNSP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CNS PHARMACEUTICALS INC stock?

8 analysts have analysed CNSP and the average price target is 204 USD. This implies a price increase of 18965.42% is expected in the next year compared to the current price of 1.07. Check the CNS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CNS PHARMACEUTICALS INC worth?

CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 3.15M USD. This makes CNSP a Nano Cap stock.


How many employees does CNS PHARMACEUTICALS INC have?

CNS PHARMACEUTICALS INC (CNSP) currently has 4 employees.


What are the support and resistance levels for CNS PHARMACEUTICALS INC (CNSP) stock?

CNS PHARMACEUTICALS INC (CNSP) has a resistance level at 1.1. Check the full technical report for a detailed analysis of CNSP support and resistance levels.


Should I buy CNS PHARMACEUTICALS INC (CNSP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CNS PHARMACEUTICALS INC (CNSP) stock pay dividends?

CNSP does not pay a dividend.


When does CNS PHARMACEUTICALS INC (CNSP) report earnings?

CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of CNS PHARMACEUTICALS INC (CNSP)?

CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-810).


What is the Short Interest ratio of CNS PHARMACEUTICALS INC (CNSP) stock?

The outstanding short interest for CNS PHARMACEUTICALS INC (CNSP) is 11.56% of its float. Check the ownership tab for more information on the CNSP short interest.


CNSP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CNSP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CNSP. While CNSP seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNSP Financial Highlights

Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -810. The EPS increased by 5.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -170.76%
ROE -240.55%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%84.27%
Sales Q2Q%N/A
EPS 1Y (TTM)5.26%
Revenue 1Y (TTM)N/A

CNSP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to CNSP. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners4.34%
Ins Owners0.03%
Short Float %11.56%
Short Ratio0.02
Analysts
Analysts80
Price Target204 (18965.42%)
EPS Next Y98.72%
Revenue Next YearN/A